Remacemide

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Remacemide
Accession Number
DB06458
Description
Not Available
Type
Small Molecule
Groups
Investigational
Structure
Thumb
Weight
Average: 268.36
Monoisotopic: 268.157563272
Chemical Formula
C17H20N2O
Synonyms
Not Available
External IDs
  • AR-R-12924
  • FPL-12924
  • PR-934-423
  • PR-934423A

Pharmacology

Indication

Investigated for use/treatment in epilepsy, huntington's disease, and parkinson's disease.

Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbirateroneThe metabolism of Abiraterone can be decreased when combined with Remacemide.
AcalabrutinibThe metabolism of Acalabrutinib can be decreased when combined with Remacemide.
AcenocoumarolThe serum concentration of Acenocoumarol can be increased when it is combined with Remacemide.
AcetazolamideThe risk or severity of adverse effects can be increased when Acetazolamide is combined with Remacemide.
AcetophenazineThe risk or severity of adverse effects can be increased when Acetophenazine is combined with Remacemide.
AclidiniumRemacemide may increase the central nervous system depressant (CNS depressant) activities of Aclidinium.
AgomelatineThe risk or severity of adverse effects can be increased when Remacemide is combined with Agomelatine.
AlbendazoleThe metabolism of Albendazole can be decreased when combined with Remacemide.
AlectinibThe metabolism of Alectinib can be decreased when combined with Remacemide.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Remacemide.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

Products

Product Ingredients
IngredientUNIICASInChI Key
Remacemide HydrochlorideI1ST2B6HIM111686-79-4HYQMIUSWZXGTCC-UHFFFAOYSA-N

Categories

Drug Categories
Classification
Not classified

Chemical Identifiers

UNII
EH6763C1IC
CAS number
128298-28-2
InChI Key
YSGASDXSLKIKOD-UHFFFAOYSA-N
InChI
InChI=1S/C17H20N2O/c1-17(19-16(20)13-18,15-10-6-3-7-11-15)12-14-8-4-2-5-9-14/h2-11H,12-13,18H2,1H3,(H,19,20)
IUPAC Name
2-amino-N-(1,2-diphenylpropan-2-yl)acetamide
SMILES
CC(CC1=CC=CC=C1)(NC(=O)CN)C1=CC=CC=C1

References

General References
Not Available
ChemSpider
54551
BindingDB
50239381
ChEBI
91654
ChEMBL
CHEMBL25843
Wikipedia
Remacemide

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00895 mg/mLALOGPS
logP2.48ALOGPS
logP2.35ChemAxon
logS-4.5ALOGPS
pKa (Strongest Acidic)13.61ChemAxon
pKa (Strongest Basic)8.14ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area55.12 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity81.01 m3·mol-1ChemAxon
Polarizability30.15 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Enzymes

Kind
Protein
Organism
Humans
Pharmacological action
No
Actions
Inhibitor
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Spina E, Pisani F, Perucca E: Clinically significant pharmacokinetic drug interactions with carbamazepine. An update. Clin Pharmacokinet. 1996 Sep;31(3):198-214. doi: 10.2165/00003088-199631030-00004. [PubMed:8877250]

Drug created on March 19, 2008 10:34 / Updated on June 12, 2020 10:52

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates